AR126423A1 - Moduladores de cd38 y métodos de uso de los mismos - Google Patents
Moduladores de cd38 y métodos de uso de los mismosInfo
- Publication number
- AR126423A1 AR126423A1 ARP220101810A ARP220101810A AR126423A1 AR 126423 A1 AR126423 A1 AR 126423A1 AR P220101810 A ARP220101810 A AR P220101810A AR P220101810 A ARP220101810 A AR P220101810A AR 126423 A1 AR126423 A1 AR 126423A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- halo
- alkyl
- formula
- alkoxy
- Prior art date
Links
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 title 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 title 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 12
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 6
- 150000003839 salts Chemical class 0.000 abstract 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 5
- 125000004076 pyridyl group Chemical group 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006714 (C3-C10) heterocyclyl group Chemical group 0.000 abstract 1
- -1 C(O)-C1−6 alkoxy Chemical group 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Se proporciona un compuesto de fórmula (1), o un estereoisómero o tautómero del mismo o una sal farmacéuticamente aceptable de cualquiera de los anteriores, en donde A, B, X¹, X², X³, y X⁴ son como se definen en la presente. También se proporciona una composición farmacéuticamente aceptable que comprende un compuesto de fórmula (1), o un estereoisómero o tautómero del mismo o una sal farmacéuticamente aceptable de cualquiera de los anteriores. También se proporcionan métodos para utilizar un compuesto de fórmula (I), o un estereoisómero o tautómero del mismo o una sal farmacéuticamente aceptable de cualquiera de los anteriores. Reivindicación 1: Un compuesto de fórmula (1), o un estereoisómero o tautómero del mismo, o una sal farmacéuticamente aceptable de cualquiera de los anteriores, en donde: X¹ es N o CH; X² es N o C(Rˣ), en donde Rˣ es H, halo, o alquilo C₁₋₆; X³ es N o C(Rʸ), en donde Rʸ es H, -OH, alcoxi C₁₋₆, cicloalquilo C₃₋₁₀, heterociclilo de 3 - 10 miembros o alquilo C₁₋₆, En donde el alcoxi C₁₋₆ de Rʸ está opcionalmente sustituido por uno o más de alcoxi C₁₋₆, el cicloalquilo C₃₋₁₀ de Rʸ está opcionalmente sustituido con uno o más halo, alcoxi C₁₋₆, o -OH, el heterociclilo de 3 - 10 miembros de Rʸ está opcionalmente sustituido con uno o más alquilo C₁₋₆, y el alquilo C₁₋₆ de Rʸ está opcionalmente sustituido con uno o más halo o -OH; X⁴ es N o C(Rᶻ), en donde Rᶻ es H, halo, -NH₂, alcoxi C₁₋₆ o alquilo C₁₋₆; siempre que como máximo dos de X¹, X², X³ y X⁴ sean N; el resto de fórmula (2) es: (i) un resto de fórmula (4) que está opcionalmente sustituido con uno o más -C(O)-NH₂, o (ii) un resto de fórmula (5) que está opcionalmente sustituido con uno o más alquilo C₁₋₆, o (iii) un resto de fórmula (6), o (iv) un resto de fórmula (7); y el resto de fórmula (3) es: (i) cicloalquilo C₄₋₉, en donde el cicloalquilo C₄₋₉ está opcionalmente sustituido con uno o más Rᵃ, en donde cada Rᵃ es independientemente -OH, halo, alquilo C₁₋₆, haloalquilo C₁₋₆, alcoxi C₁₋₆, -C(O)-alcoxi C₁₋₆, -NH(haloalquilo C₁₋₆), fenilo, fenoxi, o piridinilo, en donde el alcoxi C₁₋₆ de Rᵃ está opcionalmente sustituido por uno o más halo, fenilo o alcoxi C₁₋₆, el alquilo C₁₋₆ de Rᵃ está opcionalmente sustituido con uno o más -OH o alcoxi C₁₋₆, el fenilo de Rᵃ está opcionalmente sustituido por uno o más halo o alcoxi C₁₋₆, y el piridinilo de Rᵃ está opcionalmente sustituido por uno o más haloalquilo C₁₋₆, o (ii) heterociclilo de 4 - 9 miembros, en donde el heterociclilo de 4 - 9 miembros está opcionalmente sustituido con uno o más Rᵇ, en donde cada Rᵇ es independientemente halo, alquilo C₁₋₆, oxo, alquilo-C(O)-C₁₋₆, alcoxi-C(O)-C₁₋₆, o fenilo, en donde el fenilo de Rᵇ está opcionalmente sustituido con uno o más haloalquilo C₁₋₆, o (iii) fenilo, en donde el fenilo está opcionalmente sustituido con uno o más halo, o con alquilo C₁₋₆ opcionalmente sustituido con -OH, o (iv) piridinilo, en donde el piridinilo está opcionalmente sustituido con uno o más halo, haloalquilo C₁₋₆, alcoxi C₁₋₆ opcionalmente sustituido con uno o más halo, alquilo C₁₋₆ opcionalmente sustituido con -OH, o -O-cicloalquilo C₃₋₁₀ opcionalmente sustituido con uno o más halo; si el compuesto de la fórmula (1) o el estereoisómero o tautómero de este, o la sal farmacéuticamente aceptable de cualquiera de los anteriores, no es un compuesto que se selecciona de: la Tabla 1X, Tabla 2X, Tabla 3X, Tabla 4X, Tabla 5X, o Tabla 6X, o un estereoisómero o tautómero de este, o una sal farmacéuticamente aceptable de cualquiera de los anteriores.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163203190P | 2021-07-12 | 2021-07-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR126423A1 true AR126423A1 (es) | 2023-10-11 |
Family
ID=82786710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220101810A AR126423A1 (es) | 2021-07-12 | 2022-07-11 | Moduladores de cd38 y métodos de uso de los mismos |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230116972A1 (es) |
EP (1) | EP4370512A1 (es) |
KR (1) | KR20240047371A (es) |
CN (1) | CN117813296A (es) |
AR (1) | AR126423A1 (es) |
AU (1) | AU2022310682A1 (es) |
CA (1) | CA3225785A1 (es) |
IL (1) | IL310096A (es) |
TW (1) | TW202310835A (es) |
WO (1) | WO2023288195A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023235880A1 (en) * | 2022-06-02 | 2023-12-07 | Aeovian Pharmaceuticals, Inc. | Cd38 modulators and uses thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
AU707748B2 (en) | 1994-03-25 | 1999-07-22 | Isotechnika Inc. | Enhancement of the efficacy of drugs by deuteration |
WO2015186114A1 (en) * | 2014-06-06 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof |
RU2017121002A (ru) * | 2014-12-03 | 2019-01-11 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Ингибиторы CD38 и способы лечения |
WO2021021986A1 (en) * | 2019-07-31 | 2021-02-04 | Ribon Therapeutics, Inc. | Heterobicyclic amides as inhibitors of cd38 |
WO2021087087A1 (en) * | 2019-10-30 | 2021-05-06 | Mitobridge Inc. | N-cyclohexyl-5-(thiazol-5-yl)-1h-indole-7-carboxamide derivatives and related compounds as cd38 inhibitors for increasing nad+ and for the treatment of e.g. muscular disorders |
EP4132919A1 (en) * | 2020-04-07 | 2023-02-15 | Mitobridge, Inc. | Cd38 inhibitors |
CA3195121A1 (en) * | 2020-10-09 | 2022-04-14 | Robert A. Volkmann | Heteroaryl amide inhibitors of cd38 |
-
2022
- 2022-07-11 KR KR1020247004497A patent/KR20240047371A/ko unknown
- 2022-07-11 CA CA3225785A patent/CA3225785A1/en active Pending
- 2022-07-11 TW TW111125928A patent/TW202310835A/zh unknown
- 2022-07-11 AU AU2022310682A patent/AU2022310682A1/en active Pending
- 2022-07-11 EP EP22750980.9A patent/EP4370512A1/en active Pending
- 2022-07-11 US US17/811,790 patent/US20230116972A1/en active Pending
- 2022-07-11 AR ARP220101810A patent/AR126423A1/es unknown
- 2022-07-11 IL IL310096A patent/IL310096A/en unknown
- 2022-07-11 WO PCT/US2022/073596 patent/WO2023288195A1/en active Application Filing
- 2022-07-11 CN CN202280049080.2A patent/CN117813296A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022310682A1 (en) | 2024-01-25 |
TW202310835A (zh) | 2023-03-16 |
EP4370512A1 (en) | 2024-05-22 |
WO2023288195A1 (en) | 2023-01-19 |
US20230116972A1 (en) | 2023-04-20 |
CN117813296A (zh) | 2024-04-02 |
KR20240047371A (ko) | 2024-04-12 |
CA3225785A1 (en) | 2023-01-19 |
IL310096A (en) | 2024-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR113964A1 (es) | Carbamoíl ciclohexil ácidos ligados a n de triazol como antagonistas de lpa | |
AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
AR108203A1 (es) | Compuestos, composiciones y métodos para modular cftr (regulador de la conductancia transmembrana de la fibrosis quística) | |
PE20230376A1 (es) | Compuestos moduladores de la diacilglicerol quinasa | |
AR117616A1 (es) | Compuestos anti-vih | |
AR109709A1 (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
AR114793A1 (es) | Moduladores de enzimas modificadoras de metilo, composiciones y usos de los mismos | |
AR079486A1 (es) | Compuestos heterociclicos nitrogenados de oxima, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades proliferativas. | |
AR037329A1 (es) | Compuestos pirazolo pirimidinona, procedimientos para la preparacion de los mismos, composiciones farmaceuticas de los mismos y usos de los mismos en la preparacion de medicamentos | |
AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
AR117424A1 (es) | Inhibidores de los receptores erbb | |
AR126423A1 (es) | Moduladores de cd38 y métodos de uso de los mismos | |
AR089671A1 (es) | 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b | |
AR104306A1 (es) | Tetralinas de ácido 3-espiro-7-hidroxámico como inhibidores de hdac | |
AR080859A1 (es) | Derivados 1,2,4 triazolo-piridinicos inhibidores no nucleosidicos de la transcriptasa inversa, utiles para tratar infecciones por vih y composiciones farmaceuticas que los contienen. | |
AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
AR112831A1 (es) | Terapia de combinación usando un antagonista del receptor 2 de quimiocina (ccr2) y un inhibidor de pd-1 / pd-l1 | |
AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
AR116798A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
AR095310A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
JP2019512515A5 (es) | ||
AR120773A1 (es) | Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona como reductor de la actividad de la proteína wiz | |
RU2016151973A (ru) | Пиридиноны, замещенные фенилом и трет-бутилуксусной кислотой, обладающие анти-вич эффектами |